Clinical Dosage Calculator
Search for your condition and get step-by-step dosage calculations for immunoglobulin therapy
Popular Conditions
Dosage Guide
OR select from dropdowns below:
Select a department and disease to see dosage instructions.
Ig Dose Calculator
Clinical Education Center
Comprehensive resources for immunoglobulin therapy, dosing guidelines, and clinical best practices
What is Immunoglobulin Therapy?
Immunoglobulin (Ig) therapy involves the administration of purified, polyclonal immunoglobulin G (IgG) antibodies derived from the plasma of thousands of healthy donors. This therapy serves two primary purposes:
- Replacement Therapy: For patients with primary or secondary immunodeficiencies who are unable to produce sufficient functional antibodies to fight infections.
- Immunomodulation: For patients with autoimmune or inflammatory conditions, where high doses of Ig modulate the immune system to reduce autoantibody production, block Fc receptors, or modulate cytokine activity.
Ig products contain a broad spectrum of IgG antibodies against various bacterial and viral pathogens, reflecting the donor population's exposure history.
Types of Immunoglobulin Administration:
- Intravenous Immunoglobulin (IVIg): Administered via intravenous infusion, typically in a hospital or clinic setting.
- Frequency: Usually every 3-4 weeks.
- Pros: Rapid increase in serum IgG levels, suitable for acute conditions requiring immediate effect, no patient training required.
- Cons: Requires IV access, potential for immediate and systemic adverse effects (headache, fever, chills, fatigue, nausea), higher peak IgG levels which can increase risk of certain complications.
- Subcutaneous Immunoglobulin (SCIg): Injected under the skin, often allowing for home-based self-administration.
- Frequency: Typically administered weekly, or more frequently (e.g., daily or bi-weekly).
- Pros: Home-based convenience, avoids venous access, more consistent serum IgG levels (minimizing peaks and troughs, thus potentially fewer systemic side effects and a lower risk of renal failure, hemolysis, or thrombosis), improved patient quality of life.
- Cons: Requires patient/caregiver training, common local infusion-site reactions (redness, swelling, itching, pain) which usually diminish over time, potentially larger volumes to infuse per site.
Common Indications for Immunoglobulin Therapy
Primary Immunodeficiencies (PIDs)
Ig replacement is crucial for lifelong management of inherited disorders characterized by impaired antibody production, leading to recurrent, severe infections.
- Examples: Common Variable Immunodeficiency (CVID), X-linked Agammaglobulinemia (XLA), Severe Combined Immunodeficiency (SCID) post-transplant.
- Rationale: Passive replacement of missing or dysfunctional antibodies to provide humoral immunity.
Autoimmune and Inflammatory Neurological Conditions
High-dose Ig therapy is used for its immunomodulatory effects to suppress aberrant immune responses.
- Examples: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Myasthenia Gravis (MG), Multifocal Motor Neuropathy (MMN).
- Rationale: Mechanisms include Fc receptor blockade, neutralization of autoantibodies, modulation of complement activation, and anti-inflammatory effects.
Hematological Disorders
Used to treat conditions involving autoimmune destruction of blood cells.
- Examples: Immune Thrombocytopenic Purpura (ITP), Autoimmune Hemolytic Anemia (AIHA), Hemolytic Disease of the Fetus and Newborn (HDFN).
- Rationale: Primarily through Fc receptor blockade on macrophages, preventing destruction of antibody-coated blood cells, and modulating autoantibody production.
Other Conditions
- Specific Infections: E.g., Toxic Shock Syndrome (adjunctive therapy).
- Post-Transplantation: Prevention and treatment of antibody-mediated rejection in solid organ transplantation.
- Dermatological Conditions: Pemphigus Vulgaris, Pyoderma Gangrenosum, Atopic Dermatitis.
- Rheumatological Conditions: Systemic Lupus Erythematosus (severe), Dermatomyositis, Adult-Onset Still’s Disease.
General Dosing Principles for Immunoglobulin Therapy
Ig dosing is highly individualized and depends on the specific medical condition, disease severity, patient response, pharmacokinetic profile, and patient-specific factors (e.g., age, weight, comorbidities).
Replacement Therapy (e.g., PID)
- Typical Dose: 0.4-0.6 g/kg every 3-4 weeks (BC Guidelines). Lower doses (0.2-0.4 g/kg) for less severe cases may be considered.
- Goal: Maintain IgG trough levels generally > 5 g/L. For patients with recurrent infections (especially pneumonia), targeting higher trough levels (7-10 g/L) may be more effective.
- Monitoring: Adjust dose and frequency based on clinical response (reduction in infections), infection frequency, and IgG trough levels.
Immunomodulation (e.g., Autoimmune Disorders)
- Typical Dose: High doses, often 1-2 g/kg administered over 2-5 days.
- Frequency: Can be a single course for acute conditions (e.g., GBS) or require maintenance dosing (e.g., CIDP, MG).
- Monitoring: Primarily based on clinical improvement and disease-specific biomarkers.
Important Dosing Considerations:
- Vial Sizes: Always round doses to the full vial size to minimize product waste, as Ig is a limited resource. Consult product monographs for available vial sizes.
- Initial Infusion Rate: Start with a slow infusion rate (e.g., 0.5 mg/kg/min) and gradually increase as tolerated to minimize infusion-related reactions. Patients at risk for renal dysfunction, thrombosis, or with cardiac comorbidities require slower rates and careful hydration.
- Dose by Day Allocation: For multi-day infusions (e.g., 2-5 days for induction), the total dose is divided. Some protocols may frontload higher doses on initial days.
Weight-Based Calculations: Practical Application
Key Principles for Dosing Weight:
- Actual Body Weight (ABW): Used for patients under 18 years of age, patients weighing less than ideal body weight, and during pregnancy (BC Guidelines). Also used for SCIg dosing.
- Adjusted Body Weight (AdBW): Recommended for adult patients (≥18 years) who are clinically obese or overweight, particularly for IVIg.
- Formula: AdBW = Ideal Body Weight (IBW) + 0.5 × (Actual Body Weight - IBW).
- Rationale: The volume of distribution for Ig does not significantly increase with excess adipose tissue, making ABW dosing for obese patients potentially lead to over-dosing and increased adverse effects.
- Ideal Body Weight (IBW): Calculated using formulas (e.g., Devine formula).
- Male IBW: 50.0 kg + 2.3 kg for each inch over 5 feet (152.4 cm).
- Female IBW: 45.5 kg + 2.3 kg for each inch over 5 feet (152.4 cm).
IVIg to SCIg Conversion:
For patients transitioning from IVIg to SCIg, a common conversion is to administer the total monthly IVIg dose as weekly SCIg (1:1 conversion ratio). However, this should always be guided by clinical assessment, patient response, and IgG trough levels. Individual patient factors and prior IVIg regimen should inform the final SCIg dose and frequency.
Comprehensive Pre-infusion Assessment
Prior to initiating Ig therapy, a thorough assessment is critical to identify potential risks and ensure patient safety.
- Patient History:
- Allergies (especially to Ig products, IgA deficiency with anti-IgA antibodies).
- Previous transfusion or infusion reactions (type, severity, management).
- Comorbidities: Renal dysfunction (baseline creatinine, BUN), cardiac disease (risk of fluid overload), diabetes mellitus, thrombotic risk factors (e.g., advanced age, immobility, hypercoagulable states, estrogen use).
- Current medications (especially those affecting renal function or coagulation).
- Hydration status (ensure adequate hydration before infusion, particularly for patients at risk of renal dysfunction).
- Recent vaccinations (live vaccines may be affected by Ig administration - refer to Canadian Immunization Guide).
- Physical Examination: Baseline vital signs, assessment for fluid overload.
- Laboratory Tests:
- Baseline renal function (creatinine, BUN) and electrolytes.
- Complete Blood Count (CBC) with differential.
- Baseline serum IgG levels (for PID patients to guide therapy).
- Consider IgA levels for patients with a history of allergic reactions to Ig.
- Pre-medication (as indicated):
- Antihistamines (e.g., diphenhydramine) and/or antipyretics (e.g., acetaminophen) to mitigate mild infusion-related reactions.
- Corticosteroids (e.g., hydrocortisone) for patients with a history of moderate-to-severe reactions.
- NSAIDs for headache prevention (caution in renal impairment).
Monitoring During & Post-Infusion
During Infusion:
- Vital Signs: Monitor baseline, at 15-30 minute intervals during initial infusion rate, and then as per hospital policy. More frequent monitoring if infusion rate is increased or if patient develops symptoms.
- Infusion Rate Adjustments: Slowly titrate the infusion rate upwards as tolerated. Be prepared to slow or temporarily halt the infusion if any adverse reactions occur.
- Observation for Reactions: Continuously monitor for signs and symptoms of infusion-related reactions (see below).
Post-Infusion:
- Clinical Response: Assess the patient's clinical improvement related to the primary indication.
- IgG Trough Levels: For PID patients, monitor IgG trough levels (just prior to next scheduled infusion) to ensure adequate replacement and guide dose adjustments.
- Renal Function: Repeat creatinine and BUN within 24-48 hours for high-risk patients.
- Delayed Reactions: Educate patients on potential delayed reactions (e.g., aseptic meningitis, headache, fatigue) and when to seek medical attention.
Management of Adverse Reactions to Immunoglobulin Therapy
Adverse reactions to Ig therapy can range from mild and transient to severe and life-threatening. Prompt recognition and appropriate management are crucial. The incidence and severity can be influenced by infusion rate, product osmolarity, IgA content, and patient risk factors.
Mild Reactions (Most Common)
- Headache (most common)
- Flushing, chills, fever (usually low-grade)
- Fatigue, malaise, myalgia (muscle aches)
- Nausea, vomiting
- Mild local reactions (SCIg): Redness, swelling, itching, pain at infusion site.
Management: Slow or temporarily interrupt the infusion. Administer pre-medications (antipyretics, antihistamines). Local reactions for SCIg often resolve with time, massage, or warm/cold packs.
Moderate Reactions
- Moderate fever or rigors
- Urticaria (hives), rash
- Mild dyspnea, chest tightness
- Back or joint pain
- Hypotension (transient)
Management: Stop infusion immediately. Administer IV antihistamines and/or corticosteroids. Once symptoms resolve, restart infusion at a much slower rate. Consider a different Ig product for subsequent infusions if reactions recur.
Severe Reactions (Rare but Serious)
- Anaphylaxis: Rapid onset, severe dyspnea, bronchospasm, stridor, angioedema, profound hypotension, cardiovascular collapse.
- Management: STOP infusion. Administer epinephrine IM immediately. Support airway, breathing, circulation. IV fluids, antihistamines, corticosteroids.
- Acute Kidney Injury (AKI): Often seen with high doses, rapid infusion, pre-existing renal impairment, or sucrose-stabilized products.
- Management: Stop Ig, ensure hydration, monitor renal function.
- Thrombotic Events (TE): Stroke, MI, DVT, PE. Risk factors include advanced age, immobility, pre-existing vascular disease, high dose/rapid infusion.
- Management: Recognize symptoms, evaluate, manage as per standard TE protocols. Consider antiplatelet/anticoagulant prophylaxis in high-risk patients.
- Aseptic Meningitis (AM): Severe headache, neck stiffness, photophobia, fever, nausea, vomiting, confusion (typically 6-48 hours post-infusion).
- Management: Supportive care, analgesics. Usually self-limiting. Lumbar puncture may be needed to rule out infection.
- Hemolysis: Less common, but can occur, especially in non-O blood groups with high doses.
- TRALI (Transfusion-Related Acute Lung Injury): Acute respiratory distress and non-cardiogenic pulmonary edema.
Key Resources and Clinical Guidelines
British Columbia Guidelines / Provincial Blood Coordinating Office (PBCO of BC)
- IVIg Utilization Management Program Recommendations: Provides guidance on approved medical conditions, prerequisites, and dosing for IVIg use in British Columbia. (e.g., UM.IVIG.0007. Ver. 5.0, Revision Date: 2019-07-25 and subsequent updates).
- Relevant URL: PBCO IVIg Utilization Management Guidelines (Note: Actual URL may vary with updates)
Canadian Blood Services (CBS)
- Immunoglobulin Products (Professional Education): Information on the manufacturing, use, and general considerations for Ig products in Canada.
- Blood products, human immunoglobulin and timing of immunization: Canadian Immunization Guide: Guidance on vaccine timing relative to Ig administration.
- Relevant URLs:
Bloody Easy Guides (ORBCoN - Ontario Regional Blood Coordinating Network)
- Bloody Easy 5.1: Blood Transfusions, Blood Alternatives and Transfusion Reactions: A comprehensive guide for transfusion medicine, including sections on IVIg and SCIg administration and adverse reactions.
- Bloody Easy Blood Administration Handbook: Detailed information for healthcare professionals administering blood products, including Ig.
- Relevant URLs:
Additional Reputable Resources
- AmeriPharma Specialty Care: Offers patient and professional education on IVIg dosing and administration.
- Australasian Society of Clinical Immunology and Allergy (ASCIA): Provides patient and healthcare professional information on SCIg therapy.
- DrugBank Online / NCBI Bookshelf (StatPearls): For detailed pharmacological and mechanism of action information.